Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 8/20 | 0.44 |
| ▸ | KDM1A | O60341 | 5/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484695 | 1.00 | HTR2A (0.46) | HTR2AHTR2CHTR2BACHEKDM1A | |
| Hydrochloric Acid SCHEMBL16535589 | 0.98 | ACHE (0.47) | HTR2AHTR2CHTR2BACHEKDM1A | |
| Methylamine SCHEMBL27747617 | 0.96 | HTR2A (0.47) | HTR2AHTR2CHTR2BACHEKDM1A | |
| SCHEMBL3203100 | 0.89 | ACHE (0.48) | HTR2AHTR2CHTR2BACHEKDM1A | |
| SCHEMBL3178048 | 0.89 | ACHE (0.48) | HTR2AHTR2CHTR2BACHEKDM1A | |
| SCHEMBL15188938 | 0.89 | ACHE (0.48) | HTR2AHTR2CHTR2BACHEKDM1A | |
| Hydrochloric Acid SCHEMBL3175686 | 0.87 | ACHE (0.47) | HTR2AHTR2CHTR2BACHEKDM1A | |
| SCHEMBL784874 | 0.84 | KDM1A (0.47) | HTR2AHTR2CKDM1AKDM1B | |
| SCHEMBL584522 | 0.84 | KDM1A (0.47) | HTR2AHTR2CKDM1AKDM1B | |
| SCHEMBL3215208 | 0.84 | KDM1A (0.47) | HTR2AHTR2CKDM1AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522602-B2 | Derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2026-01-13 | — | — | US | disclosed |
| EP-4389744-B1 | DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2025-12-03 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12441711-B2 | Compounds and their use for treatment of hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-14 | — | — | US | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250163025-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | disclosed |
| CN-114829361-B | Derivatives having 2, 3-dihydro-1H-indene or 2, 3-dihydrobenzofuran moiety or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-07-16 | — | — | CN | disclosed |
| WO-2021096238-A1 | NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | WO | disclosed |
| US-10000507-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170190716-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-9556197-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-31 | — | — | US | disclosed |
| EP-3036238-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | Incyte Corporation (US) | 2016-06-29 | — | — | EP | disclosed |
| CN-105658653-A | Furo- and thieno-pyridine carboxamide compounds useful as PIM kinase inhibitors | 因赛特公司 | 2016-06-08 | — | — | CN | disclosed |
| WO-2015027124-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | US | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190716-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | HTR2A 3813/4885HTR2C 3476/4885HTR2B 3426/4885 |
| US-10000507-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | PIM1, PIM2, PIM3 | HTR2A 3813/4885HTR2C 3476/4885HTR2B 3426/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | HTR2A 1602/4885HTR2C 1403/4885HTR2B 1325/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | HTR2A 2802/4885HTR2C 2611/4885HTR2B 2229/4885 |
| US-20250163025-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | HTR2A 3333/4885HTR2C 3598/4885HTR2B 3281/4885 |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | HTR2A 465/4885HTR2C 263/4885HTR2B 459/4885 |
| US-12441711-B2 | Compounds and their use for treatment of hemoglobinopathies | HBG1, HBG2, HBB | HTR2A 3333/4885HTR2C 3598/4885HTR2B 3281/4885 |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBZ, HBG2, HBB | HTR2A 3663/4885HTR2C 2776/4885HTR2B 3158/4885 |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | HTR2A 3813/4885HTR2C 3476/4885HTR2B 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.